<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01411371</url>
  </required_header>
  <id_info>
    <org_study_id>05/Q0605/47</org_study_id>
    <nct_id>NCT01411371</nct_id>
  </id_info>
  <brief_title>Catheter Ablation Versus Medical Treatment of AF in Heart Failure</brief_title>
  <acronym>CAMTAF</acronym>
  <official_title>Catheter Ablation Versus Medical Treatment of AF in Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barts &amp; The London NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>British Heart Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Barts &amp; The London NHS Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heart failure and atrial fibrillation (AF) often coexist, and each increases the morbidity
      and mortality associated with the other. The investigators hypothesized that restoration of
      normal sinus rhythm by catheter ablation is superior to medical treatment of AF in heart
      failure. This study randomizes patients with heart failure and persistent AF to medical
      treatment of AF or catheter ablation to restore sinus rhythm.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2005</start_date>
  <completion_date type="Anticipated">October 2011</completion_date>
  <primary_completion_date type="Anticipated">October 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in ejection fraction between groups</measure>
    <time_frame>6 months</time_frame>
    <description>Difference in left ventricular ejection fraction between groups on echocardiography at 6 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in peak VO2 between groups</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in NYHA class between groups</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in BNP between groups</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Quality of Life between groups</measure>
    <time_frame>6 months</time_frame>
    <description>Using SF36 and Minnessota questionaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in end systolic volume</measure>
    <time_frame>6 months compared to baseline</time_frame>
    <description>Comparisson between groups of the percentage reduction in left ventricular end systolic volume at 6 months compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in heart failure symptoms</measure>
    <time_frame>6 months</time_frame>
    <description>Comparisson between groups in heart failure symptoms using the Minessota living with heart failure questionaire.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Catheter Ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Catheter ablation of persistent atrial fibrillation to restore normal sinus rhythm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medical treatment alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients are randomised to medical treatment alone for atrial fibrillation. Treatment will be as per current guidelines for persistent atrial fibrillation, with rate control as first line (using beta-blockers, calcium channel blockers and digoxin as indicated) and rhythm control as second line (using sotalol, dronedarone, or amiodarone as indicated). (Both groups will receive standard heart failure medication including angiotensin converting enzyme inhibitors, beta blockers, aldosterone antagonists, and diuretics as indicated).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Catheter ablation of persistent atrial fibrillation</intervention_name>
    <description>Catheter ablation of AF as described previously by our group (e.g. Hunter et al, Heart 2010).</description>
    <arm_group_label>Catheter Ablation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Medical treatment alone</intervention_name>
    <description>Medical treatment of persistent AF as 'normal care'. Patients are randomised to medical treatment alone for atrial fibrillation. Treatment will be as per current guidelines for persistent atrial fibrillation, with rate control as first line (using beta-blockers, calcium channel blockers and digoxin as indicated) and rhythm control as second line (using sotalol, dronedarone, or amiodarone as indicated). (Both groups will receive standard heart failure medication including angiotensin converting enzyme inhibitors, beta blockers, aldosterone antagonists, and diuretics as indicated).</description>
    <arm_group_label>Medical treatment alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Persistent atrial fibrillation

          -  Symptomatic heart failure

        Exclusion Criteria:

          -  Reversible causes of heart failure

          -  Contraindications to catheter ablation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard J Schilling, MD FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor of Cardiology, Barts &amp; The London NHS Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ross J Hunter, MRCP</last_name>
    <phone>442076018639</phone>
    <email>ross.hunter@bartsandthelondon.nhs.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Barts &amp; The London NHS Trust</name>
      <address>
        <city>London</city>
        <state>UK</state>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ross J Hunter, MRCP</last_name>
      <phone>442076018639</phone>
      <email>ross.hunter@bartsandthelondon.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Richard J Schilling, MD FRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ross J Hunter, MRCP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2010</study_first_submitted>
  <study_first_submitted_qc>August 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2011</study_first_posted>
  <last_update_submitted>August 5, 2011</last_update_submitted>
  <last_update_submitted_qc>August 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>Professor Richard Schilling</name_title>
    <organization>Barts &amp; The London NHS Trust</organization>
  </responsible_party>
  <keyword>Atrial fibrillation</keyword>
  <keyword>Heart failure</keyword>
  <keyword>Catheter ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enzyme Inhibitors</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
    <mesh_term>Calcium Channel Blockers</mesh_term>
    <mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>September 7, 2015</submitted>
    <returned>October 8, 2015</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

